Lupin informed in a press release on Tuesday, “Lupin Formoflo-G® is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability.”
Nilesh Gupta, Managing Director, Lupin, said, “As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G® MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases.”
Rajeev Sibal, President – India Region Formulations, Lupin, said, “Formoflo-G® MDI marks an important addition to our respiratory portfolio, bringing together three established therapies in a single inhaler. It strengthens Lupin’s respiratory portfolio and provides healthcare professionals with an important treatment option for appropriate COPD patients. It reflects our commitment to delivering innovative, high-quality therapies that help improve patient outcomes.”
Ranked #2 in the respiratory therapy segment in India (IQVIA, MAT Mar 2026), Lupin continues to strengthen its leadership in respiratory care with the launch of Formoflo-G® MDI, reinforcing its focus on addressing unmet patient needs through innovation-driven therapies.
